Smart Contact Lens Tear Glucose Detection 2026
Smart Contact Lens Tear Glucose Detection
Smart contact lenses functionalized for continuous tear glucose monitoring offer a minimally invasive alternative to finger-prick testing for an estimated 537 million adults living with diabetes. This landscape maps 50+ patent filings and literature records across four principal sensing modalities.
Tear-Based Glucose Sensing: Four Modalities in One Lens
Smart contact lens tear glucose detection integrates glucose-responsive sensing elements directly into a biocompatible lens substrate to measure lacrimal fluid glucose as a non-invasive surrogate for blood glucose. The scientific premise—validated across multiple retrieved literature records—is that tear glucose concentration maintains a positive correlation with blood glucose levels.
Four principal sensing modalities appear within this dataset: electrochemical enzyme-transducer architectures using glucose oxidase coupled to nanomaterials; optical/photonic crystal sensors exploiting diffraction or reflectance shifts; colorimetric boronic acid–glucose affinity sensors; and fully integrated electronic platforms embedding microprocessors, wireless communication, and energy harvesting.
Substrate materials dominate two categories: silicone hydrogel and poly(2-hydroxyethyl methacrylate) (HEMA)-based hydrogels for their oxygen permeability and biocompatibility, and rigid gas permeable lenses for colloidal crystal sensing contexts. Wireless protocols cited across filings include NFC, Bluetooth, RF, Li-Fi, and IoT connectivity, reflecting rapid maturation of the data transmission layer.
The earliest retrieved filing dates to 2007 (GEELUX Holdings, US), with foundational nanocomposite biosensor patents from William Gerald Hodge appearing from 2008–2010. In this dataset, India leads by raw filing count with at least 14 distinct applicants filing between 2021 and 2026, while US-jurisdiction patents from Verily, BOE, Hanyang University, and Menicon represent the highest technical maturity among retrieved records.
Filing Trends and Technology Cluster Distribution
Retrieved records span 2007–2026, revealing three distinct innovation waves and a recent geographic expansion into India. Electrochemical and optical sensing clusters dominate early filings, while integrated electronic platform architectures account for the majority of 2021–2026 entries in this dataset.
Patent Filings by Technology Cluster — Retrieved Records
Integrated electronic and wireless platform patents constitute the largest cluster in this dataset, driven primarily by 2021–2026 Indian academic filings, while electrochemical and optical chemistry clusters hold the highest-quality granted patents in US and CA jurisdictions.
↗ Click bars to exploreFiling Activity by Period — Smart Contact Lens Tear Glucose (Retrieved Records)
Filing activity in this dataset accelerated markedly in the 2021–2026 period, driven by a surge of Indian academic institution submissions, compared to the foundational 2007–2012 and commercialization-oriented 2013–2020 waves.
↗ Click bars to exploreKey Application Areas Across Retrieved Smart Lens Records
Retrieved patents and literature records span four distinct application domains, from primary diabetes glucose management to multi-parameter ocular health monitoring, cognitive performance optimization, and integrated sense-and-treat theranostic platforms.
Diabetes Management & Blood Glucose Surrogacy
The dominant application across all retrieved records is non-invasive continuous glucose monitoring for diabetic patients, explicitly citing the IDF statistic of 537 million diabetic adults globally as motivation. Patents from Graphic Era University (IN, 2025) and Dr. K. Sivakumar (IN, 2021) position tear glucose measurement as a replacement or complement to finger-prick self-monitoring and subcutaneous CGMs. Tear glucose concentration is validated across multiple retrieved literature records as maintaining a positive correlation with blood glucose levels.
Wearable DiagnosticsMulti-Parameter Ocular Health Monitoring
Several retrieved patents co-integrate glucose sensing with intraocular pressure (IOP) monitoring for glaucoma, tear film osmolarity for dry eye syndrome (DES), and temperature sensing for corneal inflammation in a single lens. GLA University Mathura’s 2025 IN patent describes an integrated smart contact lens for monitoring and detecting ocular health conditions using cloud-based machine learning algorithms for biomarker abnormality detection. A 2020 literature record describes a preocular sensor system for concurrent monitoring of glucose levels and dry eye syndrome using tear fluids.
Multi-Analyte SensingCognitive Performance & Dietary Optimization
A US-filed patent by YOUNG, MICHAEL ROY (2016) proposes using tear glucose data to optimize brain glucose availability and enhance executive functions including memory, attention, and decision-making, extending the application domain beyond diabetes into performance optimization. The patent references Google’s smart contact lens platform as the measurement vehicle for delivering these cognitive benefits. This represents a distinct non-clinical application trajectory within the retrieved dataset.
Performance OptimizationTheranostics & On-Lens Drug Delivery
PHI Biomed’s smart contact lens platform (EP and US, 2018–2020) combines biosensing with a drug delivery reservoir controlled via external smart glasses, applicable to both diabetes and glaucoma management. This closed-loop theranostic architecture—where the lens both senses glucose and delivers a therapeutic response—represents the highest integration complexity among retrieved records. PHI Biomed Inc. holds filings across EP, US (2018–2024), with a remotely controlled contact lens patent active as of 2024.
Theranostic PlatformLeading Patent Assignees in Smart Contact Lens Glucose Sensing (Retrieved Records)
In this dataset, Verily Life Sciences (US) and BOE Technology Group (CN/US) represent two of the most technically differentiated assignees in core sensing architecture, each with multiple filings across distinct technology clusters between 2014 and 2022 in retrieved records. Hodge William Gerald (US/CA) and Hanyang University (KR/US) hold the most consistently active granted patents in electrochemical and nanocomposite biosensor chemistry in this dataset.
Top Assignees by Filing Count — Smart Contact Lens Glucose (Dataset Snapshot)
↗ Click bars to exploreVerily Life Sciences LLC
Verily Life Sciences (Google’s life sciences unit) filed RF-powered glucose sensor lens patents in the US between 2014 and 2018, with at least three information processing method patents retrieved in this dataset across US and AU jurisdictions. Their filings cover wireless data transmission, sensor control, and antenna integration within a contact lens substrate. Patent status includes active grants in the US jurisdiction based on retrieved records.
United StatesBOE Technology Group Co., Ltd.
BOE Technology Group holds three retrieved US patent records (2020 and 2022) on contact lens systems and methods for monitoring glucose using spectral analysis, plus a 2019 CN filing covering a photonic crystal glucose detection film and regulation system under Beijing Jingdongfang Technology Development Co., Ltd. BOE’s approach uses spectral-analysis-based optical sensing architectures, positioning it as a leading optical cluster assignee in this dataset. Retrieved US patents are active grants as of the dataset snapshot.
China — CN / United StatesFive Convergent Trends in 2024–2026 Filings
The most recent filings in this dataset (2024–2026) reveal five convergent technology directions, ranging from on-lens AI edge analytics to bioinspired microfluidic tear collection and augmented reality glucose display, signaling a shift from single-function sensing to fully integrated health management platforms.
AI-Driven Edge Analytics on the Lens
Chandigarh University’s January 2026 IN patent describes a self-powered AI-driven health monitoring contact lens where on-device machine learning processes tear biomarker data in real time, transmitting actionable health alerts to mobile apps. GLA University’s August 2025 IN patent explicitly references cloud-based machine learning algorithms for biomarker abnormality detection. These filings signal a transition from passive sensor data collection toward autonomous on-lens intelligence.
Bioinspired Microfluidic Tear Collection
Tsinghua University’s January 2026 CN patent describes a contact lens tear glucose monitoring system incorporating a bioinspired microfluidic sample collection module for improved tear capture efficiency, integrated with a wireless signal transmission module on a flexible transparent substrate. This architecture addresses one of the primary measurement challenges in tear glucose sensing: ensuring adequate and consistent tear sample volume at the sensor interface. The filing is active in the CN jurisdiction as of the dataset snapshot.
Electrochemical vs. Optical/Photonic Sensing: Key Dimensions
Click any row to explore further.
| Dimension | Electrochemical Enzyme-Based | Optical / Photonic Crystal |
|---|---|---|
| Sensing Principle | Glucose oxidase (GOx) coupled to conductive nanomaterials generates electrochemical signal proportional to glucose concentration | Glucose-responsive photonic microstructures (colloidal crystal arrays, diffraction gratings) shift diffracted/reflected wavelength upon glucose binding |
| Detection Range | Calibrated against physiological tear glucose; CeO₂-GOx systems allow colorimetric visualization | 0–50 mM glucose range reported; detection limit of 0.05 mM cited in retrieved literature |
| Wavelength / Signal Output | Electrical current or colorimetric color change (no wavelength shift) | Wavelength shifts between 567 nm and 468 nm across 0–50 mM glucose range |
| Key Assignees (Dataset) | Hanyang University (KR/US, 2020–2022), Hodge William Gerald (US/CA, 2008–2016), Sona College of Technology (IN, 2025) | BOE Technology Group (CN/US, 2019–2022), academic literature sources (2017–2020) |
| Substrate Compatibility | Silicone hydrogel and HEMA-based hydrogels cited across multiple retrieved patents | Rigid gas permeable (RGP) lenses for colloidal crystal sensing; hydrogel matrices for molecularly imprinted polymer variants |
| Wireless / Electronics Dependency | Can operate with embedded electrodes and NFC/Bluetooth readout or standalone colorimetric readout | Readable by smartphone camera without embedded electronics in some boronic acid/photonic variants; external spectrometer cited for precision measurement |
| Clinical Validation Status (Dataset) | In-vitro and in-vivo prototypes demonstrated in 2017–2018 literature; tear-blood glucose correlation remains primary unresolved challenge | In-vitro demonstrations reported; tear-blood glucose calibration under physiological variability (exercise, dry eye) remains unresolved per retrieved records |
Frequently Asked Questions: Smart Contact Lens Tear Glucose Detection
According to multiple retrieved literature records and patents, tear glucose concentration maintains a positive correlation with blood glucose levels, enabling tear-based measurements as a non-invasive surrogate for blood glucose monitoring. This correlation has been validated in in-vitro and in-vivo prototypes reported in literature from 2017–2018.
The four principal modalities identified within this dataset are: (1) electrochemical enzyme-transducer architectures using glucose oxidase coupled to nanomaterials; (2) optical/photonic crystal sensors exploiting diffraction or reflectance wavelength shifts; (3) colorimetric/chemical sensors based on boronic acid–glucose interactions; and (4) fully integrated electronic platforms with microprocessors, wireless communication, and energy harvesting.
In this dataset, key assignees include Verily Life Sciences LLC (US, RF-powered lens, 2014–2018), BOE Technology Group (CN/US, spectral analysis, 2019–2022), Hodge William Gerald (US/CA, nanocomposite biosensors, 2008–2016), Hanyang University (KR/US, nanoparticle-enzyme complexes, 2020–2022), Menicon Co., Ltd. (JP/US, 2019–2024), IBM Corporation (US, Li-Fi data transfer, 2018–2020), and PHI Biomed (KR/US/EP, theranostic platform, 2018–2024).
Within this dataset, at least 14 distinct Indian academic and technical institutions filed smart contact lens patents between 2021 and 2026, with the majority filed from 2024 onward. According to the retrieved content, these Indian filings skew toward integrated electronic platform architectures rather than novel sensing chemistry, are predominantly pending in status, and represent an emerging talent and IP base that remains at proof-of-concept stage with limited clinical validation data.
Multiple retrieved literature records and patents identify the primary unresolved challenge as establishing accurate, calibrated, real-time tear-blood glucose correlation under physiological variability—including exercise, reflex tearing, and dry eye conditions. The content identifies adaptive calibration algorithms and clinical correlation studies as the highest-leverage near-term R&D opportunity.
Wireless protocols cited across retrieved filings include NFC, Bluetooth, RF, Li-Fi, and IoT connectivity. IBM Corporation’s Li-Fi data transfer architecture for smart contact lenses emerged in US filings from 2018–2020. More recent 2024–2026 filings from Indian institutions reference NFC, Bluetooth, and IoT integration, while Tsinghua University’s 2026 CN patent describes a wireless signal transmission module on a flexible transparent substrate.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.